According to the National Institutes of Health (NIH), there are over 7,000 diseases classified as rare, affecting an estimated 25-30 million Americans.

In this episode of the From Lab to Patient, Garage to Market, Phil Crowley speaks with Dr. George Calhoun & Sean Hanlon. George is Director at Hanlon Financial Systems Center at Stevens Institute of Technology.

Artificial intelligence ("AI") is all over the news these days.

We live in an extraordinary time. It's a time where technology in life sciences is peeling back the curtain on the underlying causes of disease.

Watch out! Artificial intelligence ("AI") is coming! AI is coming to healthcare and drug discovery...

In this episode of the From Lab to Patient, Garage to Market, Phil Crowley speaks with Jennifer Hawks Bland, CEO at NewYorkBIO. NewYorkBIO supports the development...

The application and advancement of artificial intelligence is one of the most discussed topics across industry sectors these days. There is no shortage of conversation about what AI holds...

From Lab to Patient, Garage to Market with Philip Crowley, Episode 27.

For founders in life sciences and other technology companies, the cap table is fragile by design. Stock is more than a piece of paper, it carries ownership and control over the company.

Just about every industry is experiencing a dramatic evolution with the sudden rise of artificial intelligence (AI). Healthcare and pharmaceuticals are no different.

Founders of startups and leaders of young companies have plenty on their plates. It's tempting for entrepreneurs to focus their attention on immediate priorities. Others prefer to spend their time scratching their innate itch for innovation.

That's especially true for startups new to the field. But it need not be. The process serves an important purpose—ensuring that new drugs and medical devices marketed to the public are safe, effective, and result in the intended health outcomes.

Is artificial intelligence a boon or a bane—or perhaps a bit of both?

The realm of medical devices has seen remarkable advancements in 2023.

Many early-stage startup teams move fast, fueled by trust, optimism and a shared goal. But what happens when real money shows up? Or when a cofounder wants out?

Keeping to the fundamentals can be tough. As a busy startup founder, it's tempting to look for "do it yourself" stop-gap solutions for equity issues with a mantra of "we can deal with this later."

As generative AI rapidly becomes the backbone of industries like life sciences and other technology, the value of data has soared. Unfortunately, so have the risks associated with it.

Valuation of life sciences companies has been battered and the IPO window has closed, for now. But there are still plenty of strategic partners looking for promising new technology and life sciences companies to fill their pipelines.

The Investigational New Drug Application or IND is a key step in this journey.

Artificial intelligence has become a buzzword—every article, news bulletin, podcast, and other digital media seems to mention it.